Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency

Sandip Dhoot; Sanjay Mittal; Simar Pal Singh; Vishal Patel; Ravi R Kasliwal; Varshil Mehta

doi:10.2144/fsoa-2019-0156

Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency

Future Sci OA. 2020 Mar 31;6(5):FSO467. doi: 10.2144/fsoa-2019-0156.

Authors

Sandip Dhoot¹, Sanjay Mittal¹, Simar Pal Singh^{1

2}, Vishal Patel², Ravi R Kasliwal¹, Varshil Mehta²

Affiliations

¹ Department of Cardiology, Dedanta, The Medicity Hospital, Gurgaon, India.
² Chelsea & Westminster Hospital NHS Foundation Trust, West Middlesex University Hospital Site, Isleworth, UK.

Abstract

There is a very high prevalence of iron deficiency anemia in patients with systolic heart failure. The present study is a prospective, parallel, 1:1 randomized controlled trial of intravenous ferric-carboxy maltose compared with standard of care in patients with heart failure. A total of 70 patients who presented to us with symptomatic chronic heart failure were included and randomly assigned to either groups (35 per group). Post 12 weeks, there were improvements noticed in peak VO₂, New York Heart Association functional classification, 6-min walk test distance covered and reduction in Minnesota Living with Heart Failure Questionnaire score in the ferric-carboxy maltose as compared with standard of care group. However, no improvement in ejection fraction was noticed.

Keywords: MLHFQ score; New York Heart Association (NYHA) functional class; ejection fraction; ferric-carboxy maltose; ferritin; heart failure; iron deficiency; peak VO2; quality of life (QoL); six-minute walk distance.